The Efficacy and Pharmacological Mechanism of Zn7MT3 to Protect against Alzheimer’s Disease
Authors:
Open Access
- 23 October 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 13763
Abstract
Alzheimer’s disease (AD) is one of the leading causes of death for people over 65 years. Worse still, no completely effective therapeutic agent is available so far. One important pathological hallmark of AD is accumulated amyloid-β (Aβ) plaques with dysregulated metal homeostasis. Human metallothionin 3 (MT3), a regulator of metal homeostasis, is downregulated at least 30% in AD brain. So far, some in vitro studies demonstrated its multiple functions related to AD. However, it is a great pity that systematic in vivo studies of MT3 on AD model animals are still a blank so far. In this study, we treated APP/PS1 mice with sustained drug release of Zn7MT3 directly to the central nervous system, and investigated the role and molecular mechanism of Zn7MT3 to protect against AD mice systematically. The results demonstrated that Zn7MT3 can significantly ameliorate cognitive deficits, regulate metal homeostasis, abolish Aβ plaque load, and reduce oxidative stress. Additionally, it has been confirmed that MT3 is penetrable to the blood brain barrier of AD mice. All these results support that Zn7MT3 is an effective AD suppressing agent and has potential for applications in Alzheimer’s disease therapy.Keywords
This publication has 70 references indexed in Scilit:
- Micronutrients supplementation and nutritional status in cognitively impaired elderly persons: a two-month open label pilot studyNutrition Journal, 2013
- Zinc homeostasis and neurodegenerative disordersFrontiers in Aging Neuroscience, 2013
- Impaired β-Amyloid Secretion in Alzheimer's Disease PathogenesisJournal of Neuroscience, 2011
- Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunctionCell Death & Disease, 2010
- Age-associated oxidative damage to the p62 promoter: implications for Alzheimer diseaseFree Radical Biology and Medicine, 2009
- Lipid peroxidation up‐regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer’s diseaseJournal of Neurochemistry, 2008
- Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trialNutrition Journal, 2007
- Free radicals and antioxidants in normal physiological functions and human diseaseThe International Journal of Biochemistry & Cell Biology, 2007
- Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)Chemical Reviews, 2006
- Neurodegenerative diseases and oxidative stressNature Reviews Drug Discovery, 2004